103597-10-0

Upstream product

• 81691-32-9 N⁶-benzoyl-2',5'-bis-O-(tert-butyldimethylsilyl)adenosine 
• 58-61-7 adenosine 
• 1142928-70-8 6-N-benzoyl-3′-azido-2′,5′-bis-O-(tert-butyldimethylsilyl)-3′-deoxyadenosine 
• 695183-20-1 3'-azido-3'-deoxy-2',5'-bis-O-(tert-butyldimethylsilyl)-β-D-adenosine 
• 86734-95-4 9-(2,5-di-O-tert-butyldimethylsilyl-β-D-erythro-pentofuran-3-ulosyl)adenosine 
• 65109-11-7 2',5'-bis-O-(tert-butyldimethylsilyl)adenosine 
• 18055-47-5 N-Benzoyl-N,9-bis(trimethylsilyl)adenin 
• 103597-09-7 9-(3'-azido-2'-O-acetyl-5'-O-benzoyl-3'-deoxy-β-D-ribofuranosyl)-N⁶-benzoyladenine 

Downstream Products

• 1142928-71-9 N-(9-((2R,3R,4R,5S)-4-azido-3-(tert-butyldimethylsilyloxy)-5(hydroxymethyl)tetra hydro-furan-2-yl)-9H-purin-6-yl)benzamide 
• 103597-11-1 3'-deoxy-3'-(tetradecanamido)-N⁶-benzoyladenosine 
• 103627-75-4 C₆₆H₉₁ClN₁₁O₁₄PSi₂ 
• 103627-71-0 C₆₆H₈₉ClN₁₁O₁₃PSi₂ 
• 103597-12-2 3'-amino-3'-deoxy-N⁶-benzoyladenosine 

Relevant academic research and scientific papers

CYCLIC DINUCLEOTIDES AS STING AGONISTS

Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R, R1B, R1C, R2B

A practical synthesis of xylo- and arabinofuranoside precursors by diastereoselective reduction using Corey-Bakshi-Shibata catalyst

The Corey-Bakshi-Shibata (CBS) catalyst provides an efficient mechanism to reduce ketones and achieve desired enantiopure alcohols. Herein, the diastereoselective reduction of C-2′ and C-3′-keto ribofuranoside derivatives to the corresponding arabino- and xylofuranosides in greater than 95% diastereomeric excess is reported. The stereo-directed substitution with an azido group as well as the synthesis of prodrugs cytarabine and vidarabine are also described. The reported strategy offers superior diastereoselectivity, shorter reaction times, and obviates cooling required with comparable protocols involving achiral reductants.